SG151292A1 - Immunoglobulins - Google Patents

Immunoglobulins

Info

Publication number
SG151292A1
SG151292A1 SG200901959-7A SG2009019597A SG151292A1 SG 151292 A1 SG151292 A1 SG 151292A1 SG 2009019597 A SG2009019597 A SG 2009019597A SG 151292 A1 SG151292 A1 SG 151292A1
Authority
SG
Singapore
Prior art keywords
osm
immunoglobulins
modulate
interaction
antibodies
Prior art date
Application number
SG200901959-7A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Alexandre Eon-Duval
Volker Germaschewski
Christopher Plumpton
Nicholas Timothy Rapson
Michael Robert West
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0407197A external-priority patent/GB0407197D0/en
Priority claimed from GB0407193A external-priority patent/GB0407193D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SG151292A1 publication Critical patent/SG151292A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG200901959-7A 2004-03-30 2005-03-29 Immunoglobulins SG151292A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0407197A GB0407197D0 (en) 2004-03-30 2004-03-30 Immunoglobulins
GB0407193A GB0407193D0 (en) 2004-03-30 2004-03-30 Immunoglobulins

Publications (1)

Publication Number Publication Date
SG151292A1 true SG151292A1 (en) 2009-04-30

Family

ID=35064447

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200901959-7A SG151292A1 (en) 2004-03-30 2005-03-29 Immunoglobulins

Country Status (25)

Country Link
US (2) US7858753B2 (zh)
EP (2) EP1730191B1 (zh)
JP (1) JP4809828B2 (zh)
KR (1) KR100942849B1 (zh)
AR (1) AR048516A1 (zh)
AT (1) ATE515515T1 (zh)
AU (1) AU2005229457B2 (zh)
BR (1) BRPI0509367A (zh)
CA (1) CA2562953A1 (zh)
CY (1) CY1112192T1 (zh)
DK (1) DK1730191T3 (zh)
HK (1) HK1103747A1 (zh)
HR (1) HRP20110657T1 (zh)
IL (1) IL178119A0 (zh)
MA (1) MA28541B1 (zh)
NO (1) NO20064886L (zh)
NZ (1) NZ550225A (zh)
PE (1) PE20060287A1 (zh)
PL (1) PL1730191T3 (zh)
PT (1) PT1730191E (zh)
RU (5) RU2429245C2 (zh)
SG (1) SG151292A1 (zh)
SI (1) SI1730191T1 (zh)
TW (1) TWI365746B (zh)
WO (1) WO2005095457A2 (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CN101432302A (zh) 2005-11-30 2009-05-13 艾博特公司 抗－Aβ球聚体抗体，其抗原结合部分，相应的杂交瘤、核酸、载体、宿主细胞，生产所述抗体的方法，包含所述抗体的组合物，所述抗体的应用以及使用所述抗体的方法
CA2631195C (en) 2005-11-30 2016-04-05 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
WO2007098547A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
MY157173A (en) 2006-05-25 2016-05-13 Glaxo Group Ltd Modified humanised anti-interleukin-18
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
CA2730201C (en) 2008-07-10 2019-02-05 Toray Industries, Inc. Anti-cd179b antibody
CN106039307A (zh) 2008-08-05 2016-10-26 东丽株式会社 用于治疗和预防癌症的药物组合物
EP2328934A4 (en) * 2008-08-26 2013-04-03 Macrogenics Inc T cell Receptor Antibodies and Method of Use
US8309688B2 (en) * 2008-12-30 2012-11-13 Centocor Ortho Biotech Inc. Monkey homolog of human oncostatin M and methods of use thereof
EP2258723A1 (en) * 2009-06-02 2010-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Treatment of oncostatin M receptor ß mediated heart failure
HUE030102T2 (en) 2010-02-04 2017-04-28 Toray Industries A pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment and / or prevention of cancer
CN102822335B (zh) 2010-02-04 2015-09-30 东丽株式会社 癌的治疗和/或预防用药物组合物
KR101758117B1 (ko) 2010-02-04 2017-07-14 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CN102821788B (zh) 2010-02-04 2016-11-16 东丽株式会社 癌的治疗和/或预防用药物组合物
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
AU2011313847B2 (en) * 2010-10-13 2016-07-07 Janssen Biotech, Inc. Human oncostatin M antibodies and methods of use
JO3455B1 (ar) 2010-11-23 2020-07-05 Glaxo Group Ltd بروتينات ربط مولد ضد ب أونكوستاتين m (osm )
KR101980554B1 (ko) 2011-08-04 2019-05-21 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
DK2740794T3 (en) 2011-08-04 2018-06-14 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION
JP6065592B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び／又は予防用医薬組成物
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
MX363136B (es) 2012-02-21 2019-03-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PL2818483T3 (pl) 2012-02-21 2018-01-31 Toray Industries Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
EP2818482B1 (en) 2012-02-21 2019-05-22 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer
KR102052400B1 (ko) 2012-03-30 2019-12-06 도레이 카부시키가이샤 담낭암의 치료 및/또는 예방용 의약 조성물
HUE036424T2 (hu) 2012-03-30 2018-07-30 Toray Industries Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére
ES2973474T3 (es) 2013-05-30 2024-06-20 Kiniksa Pharmaceuticals Ltd Proteínas de enlace a antígeno del receptor de oncostatina M
CN105452294B (zh) 2013-08-09 2019-08-02 东丽株式会社 癌的治疗和/或预防用药物组合物
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
CN106459182B (zh) 2013-12-30 2021-09-03 岸迈生物科技有限公司 串联fab免疫球蛋白及其用途
PL3110434T3 (pl) * 2014-02-24 2019-01-31 Takeda Gmbh Białka fuzyjne uti
EP3197480A1 (en) * 2014-09-24 2017-08-02 Universita' Degli Studi Di Padova Composition to induce bone marrow stem cell mobilization
EP3250925B1 (en) * 2015-01-29 2019-04-10 Ares Trading S.A. Immunoassays for highly positively charged proteins
NZ743881A (en) 2016-02-06 2023-11-24 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
BR112018069318A2 (pt) 2016-03-28 2019-01-22 Toray Industries composição farmacêutica para tratamento e/ou prevenção de um câncer, anticorpo ou fragmento do mesmo, combinação farmacêutica para tratamento e/ou prevenção de um câncer e método para tratar e/ou prevenir um câncer
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
AU2019263850A1 (en) 2018-05-03 2020-11-19 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
FR3090637A1 (fr) * 2018-12-21 2020-06-26 Universite De Poitiers Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
SK285046B6 (sk) 1991-07-25 2006-05-04 Idec Pharmaceuticals Corporation Chimérna protilátka, ktorá sa špecificky viaže na ľudský antigén, farmaceutický prostriedok s jej obsahom, spôsob jej výroby a použitie
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US6193969B1 (en) 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
JP3622208B2 (ja) 1993-06-11 2005-02-23 東ソー株式会社 骨粗鬆症治療方法及び治療薬
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
WO1999055369A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells

Also Published As

Publication number Publication date
AR048516A1 (es) 2006-05-03
KR100942849B1 (ko) 2010-02-17
RU2009108148A (ru) 2010-09-20
RU2429245C2 (ru) 2011-09-20
ATE515515T1 (de) 2011-07-15
IL178119A0 (en) 2006-12-31
SI1730191T1 (sl) 2011-11-30
PL1730191T3 (pl) 2011-12-30
BRPI0509367A (pt) 2007-09-11
EP1730191B1 (en) 2011-07-06
KR20060135049A (ko) 2006-12-28
WO2005095457A2 (en) 2005-10-13
NO20064886L (no) 2006-12-12
EP2404935A1 (en) 2012-01-11
HK1103747A1 (en) 2007-12-28
AU2005229457A1 (en) 2005-10-13
CY1112192T1 (el) 2015-12-09
HRP20110657T1 (hr) 2011-10-31
RU2006134477A (ru) 2008-05-10
JP4809828B2 (ja) 2011-11-09
DK1730191T3 (da) 2011-10-17
TW200602079A (en) 2006-01-16
PT1730191E (pt) 2011-10-04
WO2005095457A3 (en) 2006-04-27
AU2005229457B2 (en) 2010-11-25
US7858753B2 (en) 2010-12-28
CA2562953A1 (en) 2005-10-13
US20070286861A1 (en) 2007-12-13
NZ550225A (en) 2010-11-26
RU2009108147A (ru) 2010-09-20
TWI365746B (en) 2012-06-11
MA28541B1 (fr) 2007-04-03
US20110245470A1 (en) 2011-10-06
PE20060287A1 (es) 2006-05-16
RU2011121419A (ru) 2012-12-10
EP1730191A2 (en) 2006-12-13
JP2007530068A (ja) 2007-11-01
RU2009108149A (ru) 2010-09-20

Similar Documents

Publication Publication Date Title
SG151292A1 (en) Immunoglobulins
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
MX2007000023A (es) Anticuerpos del receptor uno de interferon alfa, y sus usos.
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
TW200709817A (en) Platform antibody compositions
MX2009006891A (es) Anticuerpos cd44.
UA92505C2 (ru) Композиции на основе антитела против cd3
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
RS28904A (en) Angiopoietin-2 specific binding agents
IL178474A0 (en) Monoclonal antibodies to hepatocyte growth factor and pharmaceutical compositions containing the same
ZA200701656B (en) Humanized anti-cment antagonists
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002089738A3 (en) Proteomimetic compounds and methods
WO2005110474A3 (en) HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
MY170404A (en) Antigen binding proteins
IL209338A0 (en) Pharmaceutical compositions containing anti-cd-3 antibodies
IL154522A0 (en) IgE RECEPTOR ANTAGONISTS
GB0324656D0 (en) A protein involved in ovarian cancer
ATE412903T1 (de) Diagnostik- und therapie- verfahren von mit c5a rezeptor verbundenen krankheiten
TH82340A (th) อิมมูโนโกลบูลิน
EA202190387A1 (ru) Антитело к cd38 человека и его применение
WO2006008266A3 (en) Factor xi-binding proteins
UA98756C2 (ru) Антитело, которое связывается с cd38, для лечения заболевания, опосредованного cd38